EU/3/10/758: Orphan designation for the treatment of post-polycythaemia vera myelofibrosis
Pomalidomide
Table of contents
Overview
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.
On 27 July 2010, orphan designation (EU/3/10/758) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for pomalidomide for the treatment of post-polycythaemia vera myelofibrosis.
Key facts
Active substance |
Pomalidomide
|
Intended use |
Treatment of post-polycythaemia vera myelofibrosis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/10/758
|
Date of designation |
27/07/2010
|
Sponsor |
Celgene Europe Limited |
Review of designation
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: